Introduction
Leading pharmaceutical company receives USFDA approval for Vasopressin 5% Dextrose Injection RTU vials, including 40-unit approval and tentative 20-unit approval, for treating vasodilatory shock in adults, expanding its injectable product portfolio in the U.S. market.
Also Read: Sona BLW Precision: Stock jumps after receiving 3 PLI certifications of EVs
Share price movement of Gland Pharma
On August 26, 2025, Gland Pharma Ltd opened at ₹1964.35, up 1.18% from its previous close of ₹1941.95. The stock reached a high of ₹1964.35 and a low of ₹1915.00. By 2:13 PM, it traded at ₹1940.00, a 0.10% decrease, with a market cap of ₹31,962.75 crore.
Gland Pharma Gets USFDA Approval for Vasopressin
Gland Pharma Limited has received USFDA approval for Vasopressin 5% Dextrose Injection USP, 40 Units per 100 mL RTU vials. The company also received tentative approval for 20 Units per 100 mL RTU vials.
The product is bioequivalent and therapeutically equivalent to VASOSTRICT Injection by PH Health. It is indicated to increase blood pressure in adults with vasodilatory shock. US sales of this product were approximately USD 45 million for the year ending June 2025.
Stock performance of Gland Pharma for Period of 1 week, 6 months, and 1 year
Gland Pharma Ltd delivered a -0.18% return over the past week. The stock gained 20.0% in the past six months and 4.68% over the past year.
Also Read: BLS International: Stock jumps 3% after receiving ₹2,055.35 Cr order from UIDAI
Shareholding pattern of Gland Pharma
| Particulars | Jun 2025 | Mar 2025 | Dec 2024 |
| Promoter | 51.80% | 51.80% | 51.80% |
| FII | 7.40% | 6.90% | 5.00% |
| DII | 32.90% | 33.30% | 34.80% |
| Public | 7.90% | 8% | 8.30% |
About Gland Pharma
Gland Pharma Limited (NSE: GLAND), established in 1978, is a leading injectable-focused pharmaceutical company with a global presence in 60 countries, specializing in developing, manufacturing, and marketing sterile injectables across various dosage forms and therapies.
Stay Ahead with the Latest Stock Market Updates – Click Here
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.
FAQs
A: The stock rose after receiving USFDA approval for Vasopressin 5% Dextrose Injection RTU vials, including 40-unit approval and tentative 20-unit approval.
A: The company specializes in developing, manufacturing, and marketing sterile injectable products, including vials, ampoules, pre-filled syringes, and lyophilized formulations.
A: Gland Pharma Ltd has a market capitalization of ₹31,962.75 crore as of August 26, 2025.


